MDI Therapeutics, Inc. is a biotechnology and pharmaceutical startup based in the United States, founded in 2016. The company focuses on developing novel serpin-based therapies for the treatment of fibrosis and fibroproliferative disorders. Their recent achievement includes a significant Series A investment of $9.00M led by Juvenescence, which took place on 21 March 2022. MDI Therapeutics' dedication to pioneering treatments in this critical medical space demonstrates their potential for growth and impact in the healthcare industry. With their innovative approach and the support of notable investors, the future looks promising for MDI Therapeutics, Inc.
No recent news or press coverage available for MDI Therapeutics, Inc..